A Phase 1 interventional study of BDTX-189 in Solid Tumor, sponsored by Black Diamond Therapeutics, Inc.. Terminated at 38 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-17.
Sponsored by Black Diamond Therapeutics, Inc. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This was a clinical study with an orally administered drug, BDTX-189 in participants with advanced solid tumors that had select mutations or alterations in human epidermal growth factor receptor 2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study were to:
BDTX-189 is an irreversible, small molecular inhibitor that is highly selective versus wild-type EGFR and potent for cancer driver mutations of the ErbB family, including extracellular, transmembrane, and kinase domain allosteric mutations of HER2, as well as EGFR and HER2 exon 20 insertion mutations. These allosteric ErbB mutations are found in 1 - 2 % of most solid tumors and enriched in some cancers with a prevalence of about 2 - 7% such as in non-small cell lung cancer, breast cancer, colorectal cancer, bladder cancer, and endometrial cancer. Currently approved HER2 and EGFR directed therapies are not active against the spectrum of allosteric mutations at relevant and tolerated exposure levels.
This Phase 1/2 multi-center, open-label trial was a first-in-human study that evaluated BDTX-189 orally administered daily as a single agent in patients with solid tumors harboring select mutations or alterations. The Phase 1 portion was a dose escalation primarily designed to assess the safety and tolerability of BDTX-189 and to determine a recommended Phase 2 dose (RP2D). Phase 1 focused on patients with a solid tumor and with alterations such as:
Eligible mutations must have been determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.
The Phase 2 portion was not initiated.
Black Diamond Therapeutics, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Main Inclusion Criteria:
Phase 1 Only:
Solid tumor patients with alterations that may be associated with antitumor activity based on preclinical data for BDTX-189 such as:
Eligible mutations must be determined by a validated next-generation sequencing (NGS) test routinely used by each institution and performed in a CLIA-certified or equivalent laboratory.
Main Exclusion Criteria:
Clinical laboratory values meeting the following criteria within 4 weeks (28 days) prior to baseline:
Hematologic function:
Significant cardiovascular disease, including:
findings meeting any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Part A, cohorts of patients with select HER2, HER3, or EGFR alterations received increasing doses of BDTX-189.
Drug: BDTX-189
Participants received a daily, oral dose of BDTX-189 as part of a 3 week cycle.
Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D)
Certain toxicities will be considered dose-limiting unless clearly attributable to an extraneous cause, such as underlying disease.
Time frame: After the first dose of treatment for up to 21 days.
Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189
Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.
Time frame: From Cycle 1 Day 1 (each cycle is 21 days) until 30 days post last dose
Phase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics
Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.
Time frame: Multiple time points during Cycles 1-4 (each cycle is 21 days)
Phase 1: Objective Response Rate as a Preliminary Measure of Antitumor Activity
Objective response is defined as the proportion of participants who achieved a complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.
Time frame: Assessed until disease progression or death for up to 12 months
Phase 1: Progression-free Survival as a Measure of Antitumor Activity
Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.
Time frame: Assessed until disease progression or death for up to 12 months
| Milestone | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD Not Fasted | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Phase 1 Safety Expansion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 1 | 1 | 1 | 2 | 10 | 18 | 13 | 7 | 6 | 4 | 6 | 5 | 17 |
| Completed | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 1 | 0 | 0 | 1 | 0 | 1 |
| Not completed | 1 | 1 | 1 | 2 | 10 | 16 | 10 | 6 | 6 | 4 | 5 | 5 | 16 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 | 1 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 2 | 7 | 2 | 2 | 1 | 1 | 1 | 0 | 10 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 1 | 2 | 8 | 5 | 3 | 4 | 1 | 3 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 1 | 0 | 0 | 2 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Started new therapy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Study terminated early by sponsor | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
Certain toxicities will be considered dose-limiting unless clearly attributable to an extraneous cause, such as underlying disease.
| participants | 25 mg QD | 50 mg QD | 100 mg QD | 200 mg QD | 400 mg QD | 800 mg QD Fasted | 800 mg QD Not Fasted | 1000 mg QD | 1200 mg QD | 400 mg BID | 600 mg BID | 800 mg BID | Safety Expansion Set 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Dose Limiting Toxicities as a Determinant of the Recommended Phase 2 Dose (RP2D) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 3 | 3 | 1 |
Adverse events will be assessed by National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.
| Participants | 25 mg QD | 50 mg QD | 100 mg QD | 200 mg QD | 400 mg QD | 800 mg QD Fasted | 800 mg QD Not Fasted | 1000 mg QD | 1200 mg QD | 400 mg BID | 600 mg BID | 800 mg BID | Safety Expansion Set 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Incidence of Treatment-emergent Adverse Events as a Measure of Safety and Tolerability of BDTX-189 | 0 | 0 | 0 | 2 | 10 | 18 | 13 | 7 | 6 | 4 | 6 | 5 | 17 |
Blood samples will be taken to measure the plasma concentrations of BDTX-189 in both a fed and fasted state.
| Nanogram per mililiter (ng/mL) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Plasma Concentration of BDTX-189 as a Measure of Pharmacokinetics | NA ± NA | NA ± NA | NA ± NA | 151 ± 67.5 | 170 ± 104 | 268 ± 72.7 | 341 ± 46.4 | 0 ± 0 | 352 ± 77.8 | 123 ± 133 | 84.5 ± 39 | 165 ± 53.8 | 248 ± 77.8 |
Objective response is defined as the proportion of participants who achieved a complete response (CR; disappearance of all target and non-target lesions) or partial response (PR; at least a 30% decrease from baseline in the sum of diameters of target lesions) per RECIST version 1.1.
| Participants | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Complete response (CR) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Partial response (PR) | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 1 | 0 | 0 | 0 | 0 |
| Stable disease (SD) | 0 | 1 | 1 | 0 | 4 | 9 | 3 | 0 | 1 | 2 | 4 | 1 | 7 |
| Non-complete response/non-partial response (non-CR/non-PR) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 1 | 0 | 0 | 0 | 0 | 0 |
| Progressive disease (PD) | 1 | 0 | 0 | 2 | 6 | 4 | 5 | 3 | 2 | 1 | 2 | 3 | 8 |
| Not evaluable (NE) | 0 | 0 | 0 | 0 | 0 | 3 | 1 | 3 | 2 | 1 | 0 | 1 | 2 |
Progression-free survival is the time from first study dose until disease progression (PD; target lesion increase of 20% and at least 5mm from smallest on-study lesion sum, the appearance of new lesions, or unequivocal progression of non-target lesions) per RECIST v1.1.
| Months | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phase 1: Progression-free Survival as a Measure of Antitumor Activity | 0 (0 to 0) | 0 (0 to 0) | 0 (0 to 0) | 1.61 (0.941 to 2.279) | 1.866 (0.909 to 2.115) | 2.306 (0.493 to 4.143) | 5.158 (0.502 to 11.122) | 1.416 (1.147 to 2.189) | 1.572 (0.429 to 2.819) | 1.508 (0.688 to 2.327) | 2.252 (1.434 to 3.482) | 1.354 (0.548 to 2.160) | 1.772 (1.428 to 3.592) |
Collected over Patients remained on-study (on-treatment) until progression, adverse event, or withdrawal of consent. Mean duration of treatment across all dose levels was 11.7 months (median was 6.6 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation 25 mg QD | 1/1 (100%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation 50 mg QD | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation 100 mg QD | 0/1 (0%) | 0/1 (0%) | 1/1 (100%) |
| Dose Escalation 200 mg QD | 0/2 (0%) | 2/2 (100%) | 2/2 (100%) |
| Dose Escalation 400 mg QD | 2/10 (20%) | 2/10 (20%) | 10/10 (100%) |
| Dose Escalation 800 mg QD | 7/18 (38.9%) | 8/18 (44.4%) | 18/18 (100%) |
| Dose Escalation 800 mg QD NF | 2/13 (15.4%) | 1/13 (7.7%) | 13/13 (100%) |
| Dose Escalation 1000 mg QD | 2/7 (28.6%) | 1/7 (14.3%) | 7/7 (100%) |
| Dose Escalation 1200 mg QD | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| Dose Escalation 400 mg BID | 1/4 (25%) | 1/4 (25%) | 4/4 (100%) |
| Dose Escalation 600 mg BID | 1/6 (16.7%) | 2/6 (33.3%) | 6/6 (100%) |
| Dose Escalation 800 mg BID | 0/5 (0%) | 3/5 (60%) | 5/5 (100%) |
| Safety Expansion 800 mg QD | 10/17 (58.8%) | 4/17 (23.5%) | 17/17 (100%) |
| Event | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| pneumoniaInfections and infestations | 0/1 | 0/1 | 0/1 | 1/2 | 1/10 | 0/18 | 0/13 | 0/7 | 1/6 | 0/4 | 1/6 | 0/5 | 0/17 |
| Anorectal infectionInfections and infestations | 0/1 | 0/1 | 0/1 | 1/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 0/5 | 0/17 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 1/4 | 1/6 | 0/5 | 0/17 |
| Acute kidney injuryRenal and urinary disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 1/7 | 0/6 | 0/4 | 0/6 | 1/5 | 0/17 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 1/6 | 1/5 | 0/17 |
| AnemiaBlood and lymphatic system disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 1/5 | 0/17 |
| Cardiac tamponadeCardiac disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 1/5 | 0/17 |
| Pericardial effusionCardiac disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 1/5 | 0/17 |
| Large intestinal hemorrhageGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 1/5 | 0/17 |
| Abdominal painGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 1/6 | 0/4 | 0/6 | 0/5 | 0/17 |
| Event | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DiarrheaGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 5/10 | 12/18 | 9/13 | 5/7 | 4/6 | 4/4 | 5/6 | 5/5 | 12/17 |
| Decreased appetiteMetabolism and nutrition disorders | 1/1 | 1/1 | 0/1 | 0/2 | 2/10 | 5/18 | 1/13 | 2/7 | 0/6 | 2/4 | 1/6 | 2/5 | 3/17 |
| Back painMusculoskeletal and connective tissue disorders | 1/1 | 0/1 | 1/1 | 0/2 | 1/10 | 3/18 | 2/13 | 1/7 | 0/6 | 1/4 | 0/6 | 0/5 | 0/17 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/1 | 1/1 | 0/1 | 0/2 | 2/10 | 2/18 | 1/13 | 0/7 | 0/6 | 0/4 | 1/6 | 0/5 | 2/17 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 0/1 | 1/1 | 1/1 | 0/2 | 0/10 | 1/18 | 1/13 | 0/7 | 0/6 | 1/4 | 1/6 | 0/5 | 1/17 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/1 | 0/1 | 0/1 | 1/2 | 2/10 | 1/18 | 4/13 | 0/7 | 1/6 | 0/4 | 0/6 | 0/5 | 1/17 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/1 | 0/1 | 0/1 | 0/2 | 0/10 | 0/18 | 0/13 | 0/7 | 0/6 | 0/4 | 0/6 | 0/5 | 0/17 |
| VomitingGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 4/10 | 9/18 | 4/13 | 4/7 | 5/6 | 2/4 | 3/6 | 3/5 | 9/17 |
| NauseaGastrointestinal disorders | 0/1 | 0/1 | 0/1 | 0/2 | 4/10 | 10/18 | 8/13 | 4/7 | 3/6 | 3/4 | 4/6 | 3/5 | 10/17 |
| Blood bilirubin increasedInvestigations | 0/1 | 0/1 | 0/1 | 0/2 | 0/10 | 1/18 | 1/13 | 5/7 | 1/6 | 0/4 | 1/6 | 2/5 | 2/17 |
| Age, Categorical(Participants) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 1 | 0 | 1 | 1 | 4 | 9 | 10 | 4 | 6 | 0 | 4 | 5 | 7 | 52 |
| >=65 years | 0 | 1 | 0 | 1 | 6 | 9 | 3 | 3 | 0 | 4 | 2 | 0 | 10 | 39 |
| Age, Continuous(years) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 56 | 65 | 51 | 60 ± 17.0 | 64.5 ± 9.48 | 65.4 ± 11.94 | 60.2 ± 7.00 | 61.4 ± 7.00 | 55.8 ± 6.59 | 71.0 ± 6.06 | 59.3 ± 11.99 | 58.0 ± 5.70 | 65.3 ± 10.34 | 63.1 ± 10.26 |
| Sex: Female, Male(Participants) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 0 | 1 | 0 | 1 | 5 | 9 | 9 | 4 | 6 | 3 | 5 | 3 | 8 | 54 |
| Male | 1 | 0 | 1 | 1 | 5 | 9 | 4 | 3 | 0 | 1 | 1 | 2 | 9 | 37 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 1 | 2 | 1 | 0 | 2 | 0 | 1 | 0 | 5 | 12 |
| Not Hispanic or Latino | 1 | 1 | 1 | 2 | 9 | 15 | 11 | 6 | 4 | 4 | 4 | 5 | 11 | 74 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 5 |
| Region of Enrollment(participants) | Dose Escalation 25 mg QD | Dose Escalation 50 mg QD | Dose Escalation 100 mg QD | Dose Escalation 200 mg QD | Dose Escalation 400 mg QD | Dose Escalation 800 mg QD | Dose Escalation 800 mg QD NF | Dose Escalation 1000 mg QD | Dose Escalation 1200 mg QD | Dose Escalation 400 mg BID | Dose Escalation 600 mg BID | Dose Escalation 800 mg BID | Safety Expansion 800 mg QD | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 1 | 1 | 1 | 2 | 10 | 18 | 13 | 7 | 6 | 4 | 6 | 5 | 12 | 86 |
| Spain | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Sep 2022, 32 months.
Results were first posted in Apr 2025, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Black Diamond Therapeutics, Inc.